Bioinvent: Difference between revisions

Content deleted Content added

Inline

Revision as of 07:20, 2 June 2019

BioInvent International is a Swedish research, pharmaceutical and life science company with focus on clinical development of antibody drugs for immunotherapy against cancer. The company was founded in 1983 by Carl Borrebaeck and is listed on the Stockholm Stock Exchange since 2001. The company's partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier.^[1]^[2]^[3]^[4]^[5]^[6]

References

External links

Official website

[1] ttps://www.avanza.se/aktier/om-aktien.html/5505/bioinvent-international

[2] ttp://www.bioinvent.com/technology/

[3] ttps://www.sydsvenskan.se/2013-10-04/bioinvent-var-pionjarer-i-parken

[4] ttps://www.avanza.se/aktier/om-bolaget.html/5505/bioinvent-international

[5] ttp://www.lum.lu.se/forskningen-som-ledde-till-miljardavtalet/

[6] ttps://www.di.se/amnen/bioinvent/

[1]

[2]

[3]

[4]

[5]

[6]

Revision as of 07:19, 2 June 2019 edit Ljuvlig (talk \| contribs) 57 edits mNo edit summary ← Previous edit		Revision as of 07:20, 2 June 2019 edit undo Ljuvlig (talk \| contribs) 57 edits mNo edit summary Next edit →
Line 1:		Line 1:
	'''BioInvent International''' is a Swedish research, pharmaceutical and life science company with focus on clinical development of antibody drugs for immunotherapy against cancer. The company was founded in 1983 by Carl Borrebaeck and is listed on the Stockholm Stock Exchange since 2001. The company's partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier.<ref>https://www.avanza.se/aktier/om-aktien.html/5505/bioinvent-international</ref><ref>http://www.bioinvent.com/technology/</ref><ref>https://www.sydsvenskan.se/2013-10-04/bioinvent-var-pionjarer-i-parken</ref><ref>https://www.avanza.se/aktier/om-bolaget.html/5505/bioinvent-international</ref>		'''BioInvent International''' is a Swedish research, pharmaceutical and life science company with focus on clinical development of antibody drugs for immunotherapy against cancer. The company was founded in 1983 by Carl Borrebaeck and is listed on the Stockholm Stock Exchange since 2001. The company's partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier.<ref>https://www.avanza.se/aktier/om-aktien.html/5505/bioinvent-international</ref><ref>http://www.bioinvent.com/technology/</ref><ref>https://www.sydsvenskan.se/2013-10-04/bioinvent-var-pionjarer-i-parken</ref><ref>https://www.avanza.se/aktier/om-bolaget.html/5505/bioinvent-international</ref><ref>http://www.lum.lu.se/forskningen-som-ledde-till-miljardavtalet/</ref><ref>https://www.di.se/amnen/bioinvent/</ref>

	== References ==		== References ==